Former OptumRx executives now defend pharmacies, not PBMs.
OptumRx is the most aggressive PBM auditor in the United States. A single flagged claim can trigger six- and seven-figure recoupments, network termination for cause, and downstream loss of UnitedHealthcare commercial, Medicare Part D, and Medicaid managed care access. We defend pharmacies nationwide before the audit closes. Every day of delay costs you leverage.
.png)
By the time the OptumRx notice arrives, the downstream exposure is already stacked. Here is what your pharmacy is actually defending against.
OptumRx audit findings routinely demand recoupments of $250K to $4M+ per matter, and the OptumRx audit team aggressively extrapolates a small sampled-claim error rate across the full look-back universe. The largest single OptumRx recoupment we have reversed was $4.7M reduced to $180K.
An OptumRx termination for cause designation flows downstream into UnitedHealthcare commercial, Medicare Part D, and Medicaid managed care networks operated by the parent enterprise. Credentialing impact across multiple payors typically lands within 30 days of the termination notice.
OptumRx audit findings on controlled substances, compounding, and high-cost specialty claims are routinely referred to DEA, DOJ, HHS-OIG, and state boards of pharmacy. A PBM finding can become a civil investigative demand, a state board complaint, or a federal healthcare fraud investigation within weeks.
Four factors make OptumRx recoupments uniquely dangerous, and uniquely defensible if you know where OptumRx is actually vulnerable.
Our bench includes a former Chief Compliance Officer of UnitedHealth Group and a former federal prosecutor. We know the OptumRx audit workflow because we built it. This is how we dismantle it.
Within 24 hours: parse every deadline in the OptumRx audit notice, place a litigation hold on the claims at issue, and preserve adjudication logs and signature records before OptumRx's evidentiary window narrows.
Claim-by-claim reconstruction: prescriber PA rationale, plan criteria at time of fill, DAW code support, signature log validation, and controlled substance recordkeeping. Every flagged claim gets its own defense memo tied to the OptumRx audit citation.
We draft and file the written OptumRx appeal, quantify the extrapolation errors, and negotiate directly with the OptumRx audit team and provider relations using relationships and playbooks from our time inside the parent enterprise.
If OptumRx refuses a reasonable resolution, we file in federal court and pair the suit with regulatory defense at DEA, HHS-OIG, and the state board so a PBM dispute does not escalate into a license action or a criminal referral.
If any of these describe your 2024 to 2026 OptumRx-billed dispensing activity, you are already in the OptumRx audit pool whether or not the notice has arrived.
Outcomes are summarized for confidentiality. Client names, precise geography, and identifying facts are redacted.
Network Reinstated
A multi-location independent pharmacy operator faced OptumRx termination for cause across all seven of its New York pharmacies based on aggregated audit findings. HLA's coordinated appeal brief across the seven pharmacies challenged the OptumRx evidentiary record on a per-claim basis and led to full network reinstatement across the OptumRx, UnitedHealthcare, and Medicare Part D footprint.
Recoupment Reversed
Multi-location independent pharmacy faced an OptumRx full-scope GLP-1 audit covering 2023 to 2025 semaglutide and tirzepatide claims. HLA reconstructed the PA chain for every flagged fill and documented extrapolation errors; final settlement reflected a 96% reduction from the original demand.
Termination Reversed
A Michigan independent pharmacy received an OptumRx termination notice tied to a desk audit of controlled substance dispenses. HLA's appeal documented OptumRx's procedural errors in the audit record and reconstructed the underlying claims; the termination was reversed and the pharmacy returned to active OptumRx network status.
Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific audit.
Eight questions that come up on almost every first call.
Before you write a single page of your OptumRx response, have a privileged conversation with attorneys who have overseen 1,500+ pharmacy audits from both sides of the table, including from inside UnitedHealth Group. Free, confidential, no retainer.
